分组 |
PR |
NR |
PD |
有效率稳定率 | |
治疗
组 |
肺癌 |
11.76% |
76.48% |
11.76% |
88.24% |
子宫颈癌 |
11.76% |
74.51% |
13.73% |
86.27% | |
对照组 |
肺癌 |
0 |
74.07% |
25.93% |
74.07% |
子宫颈癌 |
0 |
77.78% |
22.22% |
77.78% |
分组 |
总数 |
上升 |
稳定 |
下降 |
治疗组 |
102 |
20 |
74 |
8 |
对照组 |
54 |
2 |
36 |
16 |
分组 |
总数 |
显效 |
有效 |
无效 |
总有效率 | |
治疗组 |
肺癌 |
51 |
30 |
16 |
5 |
90.20% |
宫颈癌 |
51 |
29 |
15 |
7 |
86.27% | |
对照组 |
肺癌 |
27 |
11 |
10 |
6 |
77.78% |
宫颈癌 |
27 |
14 |
10 |
3 |
88.89% |
分 组 |
例数 |
鳞癌 |
腺癌 |
小细胞癌 |
其他 | |
治疗组 |
肺癌 |
17 |
7 |
8 |
1 |
1 |
宫颈癌 |
17 |
10 |
5 |
1 |
1 | |
对照组 |
肺癌 |
10 |
5 |
3 |
1 |
1 |
宫颈癌 |
10 |
5 |
4 |
0 |
4 | |
合计 |
54 |
27 |
20 |
3 |
4 |
分 组 |
Ⅰ |
Ⅱ |
Ⅲ |
Ⅳ |
Ⅴ |
例数 | |
治疗组 |
肺癌 |
0 |
4 |
6 |
7 |
0 |
17 |
宫颈癌 |
0 |
6 |
6 |
5 |
0 |
17 | |
对照组 |
肺癌 |
0 |
3 |
4 |
3 |
0 |
10 |
宫颈癌 |
0 |
4 |
3 |
3 |
0 |
10 |
|
治疗组 |
对照组 |
合计 | |||
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 | |
CR |
0 |
0 |
0 |
0 |
0 |
0 |
PR |
12.6 |
11.3 |
0 |
0 |
11.9 |
0 |
MR |
10.0 |
17.1 |
12.2 |
20.2 |
13.6 |
16.9 |
SD |
63.7 |
57.8 |
64.6 |
56.6 |
60.7 |
60.6 |
PD |
12.8 |
12.8 |
22.2 |
11.8 |
12.8 |
17.0 |
分组 |
升高 |
稳定 |
下降 |
治疗组 |
23.5 |
70.6 |
5.9 |
对照组 |
15.0 |
60.0 |
25.0 |
|
显效率 |
有效率 |
无效率 |
总有效率 | |
治疗组 |
肺癌 |
47.1 |
47.1 |
5.9 |
94.2 |
宫颈癌 |
58.8 |
29.4 |
11.8 |
88.2 | |
对照组 |
肺癌 |
30.0 |
50.0 |
20.0 |
80.0 |
宫颈癌 |
30.0 |
40.0 |
30.0 |
70.0 |
|
治疗组 |
对照组 |
合计 | |||
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 | |
CR |
0 |
0 |
0 |
0 |
0 |
0 |
PR |
11.8 |
11.8 |
0 |
0 |
11.8 |
0 |
MR |
11.8 |
17.6 |
11.1 |
22.2 |
14.7 |
16.7 |
SD |
64.7 |
58.8 |
66.7 |
55.6 |
61.7 |
61 |
PD |
11.8 |
11.8 |
22.2 |
22.2 |
11.8 |
22.2 |
分组 |
升高 |
稳定 |
下降 |
治疗组 |
20.6 |
73.5 |
5.9 |
对照组 |
5.6 |
66.7 |
27.7 |
分 组 |
显效 |
有效 |
无效 |
总有效率 | |
治疗组 |
肺癌 |
64.7 |
29.4 |
5.9 |
94.1 |
宫颈癌 |
58.9 |
35.2 |
5.9 |
94.1 | |
对照组 |
肺癌 |
44.5 |
33.3 |
22.2 |
77.8 |
宫颈癌 |
55.6 |
33.3 |
11.1 |
88.9 |
分组 |
例数 |
鳞癌 |
腺癌 |
小细胞癌 |
其他 | |
治疗组 |
肺癌 |
17 |
6 |
9 |
1 |
1 |
宫颈癌 |
17 |
11 |
4 |
0 |
2 | |
对照组 |
肺癌 |
8 |
4 |
3 |
0 |
1 |
宫颈癌 |
8 |
4 |
3 |
0 |
1 | |
合计 |
50 |
26 |
20 |
1 |
5 |
分组 |
Ⅰ |
Ⅱ |
Ⅲ |
Ⅳ |
Ⅴ |
例数 | |
治疗组 |
肺癌 |
0 |
3 |
6 |
8 |
0 |
17 |
宫颈癌 |
0 |
6 |
7 |
4 |
0 |
17 | |
对照组 |
肺癌 |
0 |
2 |
3 |
3 |
0 |
8 |
宫颈癌 |
0 |
3 |
3 |
2 |
0 |
8 |
|
治疗组 |
对照组 |
合计 | |||
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 |
肺癌 |
宫颈癌 | |
CR |
0 |
0 |
0 |
0 |
0 |
0 |
PR |
11.8 |
11.8 |
0 |
0 |
11.8 |
0 |
MR |
10.8 |
16.6 |
11.1 |
21.2 |
14.7 |
16.7 |
SD |
64.7 |
58.8 |
65.7 |
55.6 |
61.7 |
61 |
PD |
11.8 |
11.8 |
22.2 |
22.2 |
11.8 |
22.2 |
分组 |
升高 |
稳定 |
下降 |
治疗组 |
20.6 |
73.5 |
5.9 |
对照组 |
6.3 |
68.7 |
25.0 |
分 组 |
显效 |
有效 |
无效 |
总有效率 | |
治疗组 |
肺癌 |
58.8 |
29.4 |
11.8 |
88.3 |
宫颈癌 |
64.7 |
29.4 |
5.9 |
94.1 | |
对照组 |
肺癌 |
37.5 |
50.0 |
12.5 |
87.5 |
宫颈癌 |
50 |
37.5 |
12.5 |
87.5 |
组织类型 |
完全缓解 |
部分缓解 |
稳定 |
进展 |
鳞癌 |
0 |
56% |
27.5% |
7.5% |
腺癌 |
0 |
69.2% |
24% |
5.7% |
小细胞癌 |
0 |
50% |
33.3% |
16.7% |
未定型癌 |
0 |
75% |
12.5% |
12.5% |
总计 |
0 |
66.7% |
25.5% |
7.8% |
TNM |
完全缓解 |
部分缓解 |
稳定 |
进展 |
Ⅰ |
|
100% |
|
|
Ⅱ |
|
87.2% |
12.8% |
|
Ⅲ |
|
73.1% |
23.1% |
3.8% |
Ⅳ |
|
39.7% |
32.8% |
27.6% |
总计 |
|
66.7% |
23.5% |
9.8 |
主要症状 |
例数 |
显效 |
有效 |
无效 |
显效率 |
干咳无痰或少而粘 |
184 |
136 |
22 |
26 |
73.9% |
痰中带血或咯血 |
144 |
124 |
15 |
9 |
86.1% |
胸痛 |
121 |
85 |
26 |
10 |
70.3% |
气急 |
91 |
64 |
16 |
11 |
70.1% |
发热 |
46 |
32 |
2 |
15 |
69.6% |
神疲乏力 |
115 |
76 |
16 |
24 |
65.5% |
辩证分型 |
例数 |
显效 |
有效 |
无效 |
显效率 |
气虚痰湿型 |
47 |
37 |
10 |
|
78.7% |
阴虚内热型 |
61 |
46 |
15 |
|
75.4% |
气阴两虚型 |
73 |
54 |
10 |
9 |
74% |
气滞血瘀型 |
23 |
12 |
7 |
4 |
52.2% |